We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drug Industry Likes FDA’s Revised Biosimilar Analytics Guidance, But Has A Few Criticisms
Drug Industry Likes FDA’s Revised Biosimilar Analytics Guidance, But Has A Few Criticisms
The FDA’s updated draft guidance on comparative analytical assessments for biosimilars is useful and usable for developers of copycat medicines, drugmakers and trade groups expressed in public comments.